Indication
Haemophilus influenzae pharyngitis
*Haemophilus influenzae* pharyngitis is an upper respiratory tract infection characterized by acute inflammation of the pharynx and tonsillar tissues caused by the pleomorphic, Gram-negative bacterium *Haemophilus influenzae*. Read more about Haemophilus influenzae pharyngitis
65 drugs 43 manufacturers
Drugs that treat it
Common Haemophilus influenzae pharyngitis therapies.
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon*Haemophilus influenzae* pharyngitis is an upper respiratory tract infection characterized by acute inflammation of the pharynx and tonsillar tissues caused by the pleomorphic, Gram-negative bacterium *Haemophilus influenzae*.
While primarily affecting pediatric populations, it can also manifest in adults, typically arising when non-encapsulated (nontypeable) or occasionally encapsulated strains colonize the nasopharynx and breach local mucosal defenses.
Clinically, it presents with sore throat, pharyngeal erythema, tonsillar exudate, cervical lymphadenopathy, and low-grade to moderate fever.
Pathophysiologically, localized bacterial adherence and endotoxin-mediated tissue irritation drive mucosal swelling and discomfort, carrying a potential risk of contiguous spread to neighboring structures such as the middle ear, sinuses, or lower airway.
- nih.gov
*Haemophilus influenzae* pharyngitis is an upper respiratory tract infection characterized by acute inflammation of the pharynx and tonsillar tissues caused by the pleomorphic, Gram-negative bacterium *Haemophilus influenzae* Clinically, it presents with sore throat, pharyngeal erythema, tonsillar exudate, cervical lymphadenopathy, and low-grade to moderate fever
- nih.gov
*Haemophilus influenzae* pharyngitis is an upper respiratory tract infection characterized by acute inflammation of the pharynx and tonsillar tissues caused by the pleomorphic, Gram-negative bacterium *Haemophilus influenzae*
- nih.gov
While primarily affecting pediatric populations, it can also manifest in adults, typically arising when non-encapsulated (nontypeable) or occasionally encapsulated strains colonize the nasopharynx and breach local mucosal defenses
- nih.gov
While primarily affecting pediatric populations, it can also manifest in adults, typically arising when non-encapsulated (nontypeable) or occasionally encapsulated strains colonize the nasopharynx and breach local mucosal defenses
- nih.gov
While primarily affecting pediatric populations, it can also manifest in adults, typically arising when non-encapsulated (nontypeable) or occasionally encapsulated strains colonize the nasopharynx and breach local mucosal defenses Pathophysiologically, localized bacterial adherence and endotoxin-mediated tissue irritation drive mucosal swelling and discomfort, carrying a potential risk of contiguous spread to neighboring structures such as the middle ear, sinuses, or lower airway
- nih.gov
Clinically, it presents with sore throat, pharyngeal erythema, tonsillar exudate, cervical lymphadenopathy, and low-grade to moderate fever
- nih.gov
Pathophysiologically, localized bacterial adherence and endotoxin-mediated tissue irritation drive mucosal swelling and discomfort, carrying a potential risk of contiguous spread to neighboring structures such as the middle ear, sinuses, or lower airway
Personalize your experience
Follow Haemophilus influenzae pharyngitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.